Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-α-2b: Results of a randomized phase II trial of low-dose versus intermediate-dose interferon-α-2b in patients with metastatic renal cell carcinoma

Cancer

Volumn 107, Issue 9, 2006, Pages 2254-2261

  Tannir, Nizar M ^a   Cohen, Lorenzo ^a   Wang, Xuemei ^a   Thall, Peter ^a   Mathew, Paul F ^a   Jonasch, Eric ^a   Siefker Radtke, Arlene ^a   Pagliaro, Lance C ^a   Ng, Chaan S ^a   Logothetis, Christopher ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Immunotherapy; Interferon; Metastatic renal cell carcinoma; Quality of life; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; GLUCOSE; URIC ACID;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONFUSION; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DYSPEPSIA; DYSPNEA; ERECTILE DYSFUNCTION; EYE DISEASE; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; IMMUNOTHERAPY; ISCHEMIC OPTIC NEUROPATHY; KIDNEY CARCINOMA; LEUKOPENIA; LIVER DYSFUNCTION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METASTASIS; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROMUSCULAR DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SUICIDE; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2B; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33750532947     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22253     Document Type: Article

References (35)

1. Cohen HT, McGovern FJ, Renal cell carcinoma. N Engl J Med. 2005;353:2477-90.
2. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132.
3. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141.
4. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17:2859-2867.
5. Medical Research Council. Renal cancer collaborators: interferon-alfa and survival in metastatic renal cell carcinoma: early results of randomized controlled trial. Lancet 1999;353:14-17.
6. Negrier S, Perol D, Ravaud A, Chevreau C. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. Proc Am Soc Clin Oncol. 2005;23:LBA4511. Abstract.
7. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004;10:2584-2586.
8. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol. 2006;24:LBA3. Abstract.
9. Hudes G, Carducci M, Tomzcak P, et al. A phase III, randomized 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line poor-prognosis patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol. 2006;24:LBA4. Abstract.
10. Gutterman JU. Cytokine therapeutics: lessons from interferon-α. Proc Natl Acad Sci U S A. 1994;91:1198-1205.
11. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999;5:2726-2734.
12. Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res. 1998;58:808-814.
13. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar R. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289-296.
14. Cella DF, Tulsky D, Gray G, et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
15. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18:2972-2980.
16. Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz HJ, Nortier JW. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol. 2003;2:366-373.
17. Radloff LS. The CES-D scale: a new self-report depression scale for research in the general population. Appl Psychol Measure. 1977;1:385-401.
18. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC; 1999.
19. Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1959;53:457-481.
20. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;60:163-170.
21. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187-220.
22. Therneau TM, Grambsch PM. Modeling Survival Data. New York: Springer; 2000.
23. Venables WN, Ripley BD. Modern Applied Statistics with S. 4th ed. New York: Springer; 2002.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2002;92:205-216.
25. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med. 1998;338:1272-1278.
26. Coppin C, Porzsolt F, Awa A, Kumpf J, Goldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005;CD001425.
27. Kondagunta GV, Bacik J, Ishill N, et al. Pegylated interferon alpha-2B (PEG-Intron) for metastatic renal cell cancer (mRCC): results of a phase II clinical trial and biologic correlates of response. Proc Am Soc Clin Oncol. 2006;24:4528. Abstract.
28. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-443.
29. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-918.
30. Motzer RI, Rini BI, Michaelson MD, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24.
31. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol. 2005;23:380s. Abstract.
32. Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol. 2005;23:7889-7896.
33. Rini B, Rixe O, Bukowski R, et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates antitumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol. 2005;23:380s. Abstract.
34. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-2512.
35. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-2524.